Skip to main content

Advertisement

SpringerLink
Log in

Psoriatic Arthritis: Pharmacotherapy Update

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Psoriatic arthritis is a systemic disorder that causes chronic pain, altered physical appearance, and loss of function. The clinical features are diverse, but the core manifestations are psoriasis, peripheral arthritis, axial disease, enthesitis, and dactylitis. Our understanding about the psoriatic arthritis disease state, assessment, and treatment has advanced thanks to significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria, outcome measures to assess the various clinical domains, and treatment trials with agents also used for diseases such as rheumatoid arthritis and psoriasis. In particular, biologic agents, especially anti-tumor necrosis factor agents, have demonstrated significant efficacy and reasonable safety in all clinical domains of the disease, resulting in amelioration of clinical symptoms, inhibition of structural damage, and improvement in function and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Mease P: Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006, 8:348–354.

    Article  CAS  PubMed  Google Scholar 

  2. • Ritchlin CT, Kavanaugh A, Gladman DD, et al.; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387–1394. This is a summary of several years of work of GRAPPA, which began with a series of evidence-based reviews of therapy of different clinical domains of PsA, followed by discussions at meetings to attempt to gain consensus, and finalized by voting on therapy recommendations for PsA. The recommendations take a grid approach that is based on relative severity and impact of the various clinical domains of PsA.

    Article  CAS  PubMed  Google Scholar 

  3. • Gladman DD, Mease PJ, Strand V, et al.: Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007, 34:1167–1170. This is a summary of the OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) module conducted by the GRAPPA group, in which the core domains to be assessed in PsA clinical trials were determined.

    PubMed  Google Scholar 

  4. Kavanaugh AF, Ritchlin C; GRAPPA Treatment Guideline Committee: Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006, 33:1417–1421.

    PubMed  Google Scholar 

  5. Soriano ER, McHugh NJ: Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1422–1430.

    Google Scholar 

  6. Nash P: Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1431–1434.

    Google Scholar 

  7. Ritchlin CT: Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006, 33:1435–1438.

    Google Scholar 

  8. Helliwell PS: Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1439–1441.

    Google Scholar 

  9. Strober BE, Siu K, Menon K: Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006, 33:1442–1446.

    Google Scholar 

  10. Boehncke WH, Prinz J, Gottlieb AB: Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006, 33:1447–1451.

    Google Scholar 

  11. Cassell S, Kavanaugh AF: Therapies for psoriatic nail disease. J Rheumatol 2006, 33:1452–1456.

    CAS  PubMed  Google Scholar 

  12. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW: Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007, 66(Suppl 3):iii56–iii60. (Published erratum appears in Ann Rheum Dis 2008, 67:140.)

    Article  PubMed  Google Scholar 

  13. Ku IA, Imboden JB, Hsue PY, Ganz P: Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009, 73:977–985.

    Article  CAS  PubMed  Google Scholar 

  14. Kimhi O, Caspi D, Bornstein NM, et al.: Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203–209.

    Article  PubMed  Google Scholar 

  15. Gladman DD, Antoni C, Mease P, et al.: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl 2):ii14–ii17.

    Article  PubMed  Google Scholar 

  16. • de Vlam K, Gottlieb AB, Fitzgerald O: Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008, 35:1443–1448. This is a review of the current state of knowledge about biomarkers in PsA.

    PubMed  Google Scholar 

  17. Maksymowych WP, Landewé R, Tak PP, et al.: Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009, 36:1785–1791.

    Article  PubMed  Google Scholar 

  18. Maksymowych WP, Fitzgerald O, Wells GA, et al.: Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009, 36:1792–1799.

    Article  PubMed  Google Scholar 

  19. • Qureshi AA, Dominguez P, Duffin KC, et al.: Psoriatic arthritis screening tools. J Rheumatol 2008, 35:1423–1425. This is a review of the current status of questionnaires being used to screen for PsA in medical practice.

    PubMed  Google Scholar 

  20. Duffin KC, Chandran V, Gladman DD, et al.: Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008, 35:1449–1453.

    CAS  PubMed  Google Scholar 

  21. Mease PJ, Antoni CE, Gladman DD, Taylor WJ: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii49–ii54.

    Article  PubMed  Google Scholar 

  22. Mease PJ: Assessment tools in psoriatic arthritis. J Rheumatol 2008, 35:1426–1430.

    PubMed  Google Scholar 

  23. Mease PJ, van der Heijde D: Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006, 4:38–48.

    Google Scholar 

  24. Feldman SR, Krueger GG: Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii65–ii68.

    Article  PubMed  Google Scholar 

  25. Gladman DD, Mease PJ, Healy P, et al.: Outcome measures in psoriatic arthritis. J Rheumatol 2007, 34:1159–1166.

    PubMed  Google Scholar 

  26. Mease PJ, Menter MA: Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006, 54:685–704.

    Article  PubMed  Google Scholar 

  27. Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007, 34:1733–1739.

    Google Scholar 

  28. Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007, 34:1740–1745.

    PubMed  Google Scholar 

  29. Chandran V, Gottlieb A, Cook RJ, et al.: International multi-center psoriasis and psoriatic arthritis reliability trial (GRAPPA-IMPART): assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2007, 56:S789–S799.

    Google Scholar 

  30. Nash P, Clegg DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005, 64(Suppl 2):ii74–ii77.

    Article  CAS  PubMed  Google Scholar 

  31. Willkens RF, Williams HJ, Ward JR, et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376–381.

    Article  CAS  PubMed  Google Scholar 

  32. Abu-Shakra M, Gladman DD, Thorne JC, et al.: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241–245.

    CAS  PubMed  Google Scholar 

  33. Whiting-O’Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711–716.

    PubMed  Google Scholar 

  34. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37:316–328.

    Article  CAS  PubMed  Google Scholar 

  35. Kalb RE, Strober B, Weinstein G, Lebwohl M: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009, 60:824–837.

    Article  PubMed  Google Scholar 

  36. Clegg DO, Reda DJ, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2013–2020.

    Article  CAS  PubMed  Google Scholar 

  37. Gibbs A, Gogarty M, Veale D, et al.: Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006, 65(Suppl 2):216–217.

    Google Scholar 

  38. Mease PJ, Kivitz AJ, Burch FX, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264–2272.

    Article  CAS  PubMed  Google Scholar 

  39. Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712–721.

    CAS  PubMed  Google Scholar 

  40. • Sterry W, Ortonne JP, Kirkham B, et al.: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010, 340:c147. This study demonstrates excellent psoriasis skin response with etanercept in patients with severe skin disease and PsA, especially in the group that has an “induction” dose with 50 mg twice per week for 12 weeks, followed by standard dose of 50 mg/wk. The higher initial dose did not yield better arthritis, enthesitis, and dactylitis improvements, which were excellent in both dose arms.

    Article  PubMed  Google Scholar 

  41. Zaba LC, Cardinale I, Gilleaudeau P, et al.: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183–3194. (Published erratum appears in J Exp Med 2008, 205:1941.)

    Article  CAS  PubMed  Google Scholar 

  42. Antoni C, Krueger GG, de Vlam K, et al.; IMPACT 2 Trial Investigators: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150–1157.

    Article  CAS  PubMed  Google Scholar 

  43. van der Heijde D, Kavanaugh A, Gladman DD, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698–2707.

    Article  PubMed  Google Scholar 

  44. • Antoni CE, Kavanaugh A, van der Heijde D, et al.: Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008, 35:869–876. This was a long-term observational study on the effect of infliximab in PsA.

    CAS  PubMed  Google Scholar 

  45. • Raffayova H, Kungurov N, Baranauskaite A, et al.: Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: the RESPOND trial [abstract]. Arthritis Rheum 2009, 60:S470–S471. This was the first study to focus on patients with relatively early PsA (ie, within the first 4 years of disease), in which MTX monotherapy was compared with combination infliximab plus MTX. Results are outstanding, particularly in the combination group, suggesting the potential impact of treating effectively early in the disease process.

    Article  Google Scholar 

  46. Mease P, Gladman D, Ritchlin C: Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of ADEPT. Arthritis Rheum 2005, 52:3279–3289.

    Article  CAS  PubMed  Google Scholar 

  47. • Mease PJ, Ory P, Sharp JT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009, 68:702–709. This was a long-term observational study on the effect of adalimumab in PsA.

    Article  CAS  PubMed  Google Scholar 

  48. Karanikolas GN, Arida K, Komninou E, et al.: Combination of adalimumab with cyclosporine-A against single therapy in refractory psoriatic arthritis: an interim analysis of an ongoing, 12-month open, three-arm, randomized trial. Ann Rheum Dis 2009, 68:138–139.

    Google Scholar 

  49. Kavanaugh A, McInnes I, Mease P, et al.: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976–986.

    Article  CAS  PubMed  Google Scholar 

  50. • Kavanaugh A, Mease P, Krueger GG, et al.: Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2009, 68:136–137. This was a long-term observational study on the effect of golimumab in PsA.

    Google Scholar 

  51. Van den Bosch F, Manger B, Goupille P, et al.: Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010, 69:394–399.

    Article  PubMed  Google Scholar 

  52. Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423–432.

    Article  CAS  PubMed  Google Scholar 

  53. Wong K, Gladman DD, Husted J, et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997, 40:1868–1872.

    Article  CAS  PubMed  Google Scholar 

  54. Tam L, Li EK, Shang Q, et al.: TNF-alpha blockade is associated with reduction of carotid intima-media thickness for patients with active psoriatic arthritis—a pilot study [abstract]. Ann Rheum Dis 2009, 68(Suppl 3):659.

    Google Scholar 

  55. Mease PJ, Gladman DD, Keystone EC; Alefacept in Psoriatic Arthritis Study Group: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1638–1645.

    Article  CAS  PubMed  Google Scholar 

  56. Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group: Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009, 60:402–411.

    Article  PubMed  Google Scholar 

  57. Abrams JR, Lebwohl M, Guzzo C: CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243–1252.

    Article  CAS  PubMed  Google Scholar 

  58. Mease P, Genovese MC, Ritchlin C, et al.: Abatacept in psoriatic arthritis: results of a phase II study session. Arthritis Rheum 2010 (in press).

  59. • Krueger GG, Langley RG, Leonardi C, et al.: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580–592. This was the first major publication regarding the efficacy of inhibition of IL-12/23 cytokines in the treatment of psoriasis.

    Article  CAS  PubMed  Google Scholar 

  60. • Gottlieb A, Menter A, Mendelsohn A, et al.: Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633–640. This was the initial study on the effect of ustekinumab in PsA.

    Article  CAS  PubMed  Google Scholar 

  61. Kimball AB, Gordon KB, Valdes JM, et al.: Retreatment efficacy and long-term safety of the fully human, interleukin-12/23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial. Presented at the 17th Congress on the European Academy of Dermatology and Venereology. Paris, France; September 17–21, 2008.

  62. McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392–397.

    Article  CAS  PubMed  Google Scholar 

  63. Cohen SB, Dore RK, Lane NE, et al.; Denosumab Rheumatoid Arthritis Study Group: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299–1309.

    Article  CAS  PubMed  Google Scholar 

  64. • Gottlieb A, Korman NJ, Gordon KB, et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58:851–864. This was a summary of a consensus process conducted among dermatologists on treatment recommendations for PsA.

    Article  PubMed  Google Scholar 

  65. Mease PJ: Management of psoriatic arthritis. In Rheumatology, edn 5. Edited by Hochberg MC. Philadelphia, PA: Elsevier; 2010 (in press)

    Google Scholar 

Download references

Disclosure

Dr. Mease has received research grants from Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, Roche, Wyeth, and Pfizer; has served as a consultant for Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, Roche, UCB, Wyeth, and Pfizer; and has served as a speaker for Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, UCB, Wyeth, and Pfizer.

Author information

Authors and Affiliations

  1. Swedish Medical Center, Division of Rheumatology Research; Seattle Rheumatology Associates, University of Washington, 1101 Madison Street, Suite 1000, Seattle, WA, 98104, USA

    Philip J. Mease

Authors
  1. Philip J. Mease
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip J. Mease.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mease, P.J. Psoriatic Arthritis: Pharmacotherapy Update. Curr Rheumatol Rep 12, 272–280 (2010). https://doi.org/10.1007/s11926-010-0108-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0108-z

Keywords

Search

Navigation